CN100430055C - 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 - Google Patents
2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 Download PDFInfo
- Publication number
- CN100430055C CN100430055C CNB2005100160317A CN200510016031A CN100430055C CN 100430055 C CN100430055 C CN 100430055C CN B2005100160317 A CNB2005100160317 A CN B2005100160317A CN 200510016031 A CN200510016031 A CN 200510016031A CN 100430055 C CN100430055 C CN 100430055C
- Authority
- CN
- China
- Prior art keywords
- solid solution
- cyano
- methyl
- tmx
- polyvinylpyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229920000036 polyvinylpyrrolidone Polymers 0.000 title claims abstract description 29
- 239000001267 polyvinylpyrrolidone Substances 0.000 title claims abstract description 29
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 title claims abstract description 29
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 235000019253 formic acid Nutrition 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 7
- 229940013688 formic acid Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 239000013078 crystal Substances 0.000 claims abstract description 18
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 239000006104 solid solution Substances 0.000 claims description 40
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 19
- 239000003826 tablet Substances 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 abstract description 40
- 238000004090 dissolution Methods 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 5
- 201000005569 Gout Diseases 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000005755 formation reaction Methods 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000002156 mixing Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000006837 decompression Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- KFVUXNKQQOUCAH-UHFFFAOYSA-N butan-1-ol;propan-2-ol Chemical compound CC(C)O.CCCCO KFVUXNKQQOUCAH-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
项 目 | 1 | 2 | 3 | 4 | 5 | 6 | 平均 |
固溶体片溶出度(%) | 98.5 | 98.8 | 99.8 | 100.3 | 99.6 | 98.4 | 99.2 |
微粉化片溶出度(%) | 65.4 | 62.3 | 57.3 | 5 8.6 | 71.5 | 65.3 | 63.4 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100160317A CN100430055C (zh) | 2005-11-11 | 2005-11-11 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100160317A CN100430055C (zh) | 2005-11-11 | 2005-11-11 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1785182A CN1785182A (zh) | 2006-06-14 |
CN100430055C true CN100430055C (zh) | 2008-11-05 |
Family
ID=36782850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100160317A Expired - Fee Related CN100430055C (zh) | 2005-11-11 | 2005-11-11 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100430055C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102860991A (zh) * | 2012-10-10 | 2013-01-09 | 杭州华东医药集团生物工程研究所有限公司 | 一种含非布司他的药物组合物及其制备方法 |
CN103030605A (zh) * | 2012-12-14 | 2013-04-10 | 贵州信邦制药股份有限公司 | 一种非布索坦原料的制备方法和检测方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0513379A1 (en) * | 1990-11-30 | 1992-11-19 | Teijin Limited | 2-arylthiazole derivative and pharmaceutical composition containing the same |
JPH10139770A (ja) * | 1996-11-08 | 1998-05-26 | Teijin Ltd | 2−(3−シアノフェニル)チアゾール誘導体の製造法 |
WO2000000179A1 (en) * | 1998-06-27 | 2000-01-06 | Won Jin Biopharma Co., Ltd. | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof |
CN1275126A (zh) * | 1998-06-19 | 2000-11-29 | 帝人株式会社 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的多晶型体及其制备方法 |
JP2002105067A (ja) * | 2000-09-28 | 2002-04-10 | Teijin Ltd | 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
CN1379768A (zh) * | 1999-03-24 | 2002-11-13 | R·P·希拉技术股份有限公司 | 改良的水溶性药物制剂 |
CN1642546A (zh) * | 2002-03-28 | 2005-07-20 | 帝人株式会社 | 含有单一晶型的固体制剂 |
CN1686146A (zh) * | 2005-03-28 | 2005-10-26 | 李志海 | 阿德福韦酯和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
-
2005
- 2005-11-11 CN CNB2005100160317A patent/CN100430055C/zh not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0513379A1 (en) * | 1990-11-30 | 1992-11-19 | Teijin Limited | 2-arylthiazole derivative and pharmaceutical composition containing the same |
JPH10139770A (ja) * | 1996-11-08 | 1998-05-26 | Teijin Ltd | 2−(3−シアノフェニル)チアゾール誘導体の製造法 |
CN1275126A (zh) * | 1998-06-19 | 2000-11-29 | 帝人株式会社 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的多晶型体及其制备方法 |
WO2000000179A1 (en) * | 1998-06-27 | 2000-01-06 | Won Jin Biopharma Co., Ltd. | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixtures thereof |
CN1379768A (zh) * | 1999-03-24 | 2002-11-13 | R·P·希拉技术股份有限公司 | 改良的水溶性药物制剂 |
JP2002105067A (ja) * | 2000-09-28 | 2002-04-10 | Teijin Ltd | 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
CN1642546A (zh) * | 2002-03-28 | 2005-07-20 | 帝人株式会社 | 含有单一晶型的固体制剂 |
CN1686146A (zh) * | 2005-03-28 | 2005-10-26 | 李志海 | 阿德福韦酯和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1785182A (zh) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2355805B1 (en) | Rifaximin complexes | |
CN101095670B (zh) | 木犀草素磷脂复合物及其制备方法和应用 | |
CN111437302B (zh) | 黄杞叶水提后大孔树脂处理后的提取物在制备糖尿病药物中的应用及其分析方法 | |
CN109662950B (zh) | 一种含有盐酸达泊西汀的药物组合物 | |
CN111514142B (zh) | 含硝羟喹啉前药的药物组合物及其制备方法和应用 | |
EP3243823B1 (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
EP3572088B1 (en) | A panax plant extract and pharmaceutical composition and use thereof | |
CN104546686B (zh) | 一种枸橼酸莫沙必利共研磨物及其制备方法和含其药物组合物 | |
US9290452B2 (en) | Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof | |
KR20190010578A (ko) | 새로운 다파글리플로진 결정형 및 그의 제조 방법 및 용도 | |
CN100430055C (zh) | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 | |
US20200323838A1 (en) | Lenalidomide immediate release formulations | |
CN105796567B (zh) | 新利司他固体分散体及其药物制剂 | |
CN105828827A (zh) | 一种含他克莫司的药物组合物及其制备方法 | |
KR20090086686A (ko) | 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법 | |
CN114206323A (zh) | 具有改善的天然产物提取物的溶出率和崩解性的口服用制剂 | |
CN102614182A (zh) | 一种复方氨酚肾素药物组合物脂质体固体制剂 | |
US10688090B2 (en) | Vilazodone inclusion complexes, compositions and preparation thereof | |
CN112351773A (zh) | 包含他克莫司的缓释药物制剂 | |
EP2292241A1 (en) | A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof | |
CN111603450B (zh) | 一种单硝酸异山梨酯片剂及其制备工艺 | |
US20080132533A1 (en) | Solid Dispersion Comprising Tacrolimus and Entericcoated Macromolecule | |
CN101095669B (zh) | 蛇床子素磷脂复合物及其制备方法和应用 | |
WO2017219453A1 (zh) | 一种缬沙坦分散片及其制备方法 | |
CN106606786A (zh) | 一种含艾沙康唑的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI GUOCHUANG MEDICAL CO., LTD. Effective date: 20120309 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120309 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Co-patentee after: SHANGHAI GUOCHUANG MEDICINE Co.,Ltd. Patentee after: TIANJIN TAIPU PHARMACEUTICAL SCIENCE & TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: TIANJIN TAIPU PHARMACEUTICAL SCIENCE & TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180503 Address after: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin Patentee after: TIANJIN TAIPU PHARMACEUTICAL SCIENCE & TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin Co-patentee before: SHANGHAI GUOCHUANG MEDICINE Co.,Ltd. Patentee before: TIANJIN TAIPU PHARMACEUTICAL SCIENCE & TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190226 Address after: 510000 self compiled G1-201, 39 Rui he road, Whampoa District, Guangzhou, Guangdong Patentee after: GUANGZHOU LIXIN PHARMACEUTICALS CO.,LTD. Address before: 300193 Anshan West Road, Nankai District, Nankai District, Tianjin Patentee before: TIANJIN TAIPU PHARMACEUTICAL SCIENCE & TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
DD01 | Delivery of document by public notice |
Addressee: Guangzhou Lixin Pharmaceutical Co., Ltd. patent The person in charge Document name: Patent termination notice |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081105 Termination date: 20211111 |